Video explaining how Nucleome Therapeutics are developing breakthrough genomics technologies focussed on discovering the molecular basis of inflammatory disease to bring first-in-class medicines to patients.

New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how he thinks Nucleome is in a unique position to put it into practice.